On the stock market since 2019, it operates in the world of health and science. It has 725 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 64% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly above the class average — a step short of the very top.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 86% a year on average.
The company sells $502.1M a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $107 — 52% above today’s price.
A loss of $729.3M against $502.1M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 232 sells against just 55 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, BBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BBIO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.